BCVA as an Early Indicator in Treat-and-Extend Management of DME: READ-3 Post-hoc Analysis

Authors

Aly Hamza Khowaja MBBS[1,2], Kholood Janjua PharmD[2,3], Rubbia Afridi MD MPH[2,3], Zoha Zahid Fazal, MD[2], Mohammad Abdul Saqhlain Shaik[2], Mohamed Ibrahim Ahmed MD MSc[3], Muhammad Sohail Halim MD MPH[2,3], Quan Dong Nguyen MD MSc[2], Yasir Jamal Sepah MBBS[2,3]

Institutions

1. Medical College, The Aga Khan University Hospital, Karachi, Sindh, Pakistan
2. Ophthalmology, Stanford University Medicine, Palo Alto, California, United States
3. Ocular Imaging Research and Reading Center, Sunnyvale, California, United States

Correspondence

Yasir Jamal Sepah, MBBS
Assistant Professor of Ophthalmology
Byers Eye Institute, Stanford University
2370 Watson Court, Palo Alto, CA 94303
Phone: +1 (323) 546-4772
Email: yjs@stanford.edu

Submission

This manuscript is in line with the Ophthalmology Retina journal submission guidelines.

Word count

3416 words

Keywords

ocular biomarkers, precision medicine, visual acuity, OCT imaging retinal thickness, anti-VEGF, ranibizumab

Disclosure

Acknowledgments
None.

Conflict of Interest
The authors have no conflict of interest to declare.

Financial Support
This study was supported by the CDH grant and in part by NIH P30 core grant.

Data Sharing Statement
The READ-3 dataset used as part of this study manuscript can be made available on reasonable request.

Author Contributions
YJS conceptualized the study. MSH and RA executed and streamlined the study methods. AHK collected the data. MA analyzed the data. YJS presented the study findings. AHK and MSH composed the initial manuscript. All authors reviewed and approved the final draft.

Meeting Presentation
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

Running Head
BCVA as a Therapy Response Predictor in DME

Abbreviations/Acronyms

BCVA	Best-corrected visual acuity
CST	Central subfield thickness
dBCVA	Rate of change in BCVA
dCST	Rate of change in CST
DME	Diabetic macular edema
DR	Diabetic retinopathy
DRCR	Diabetic Retinopathy Clinical Research
ETDRS	Early Treatment of Diabetic Retinopathy Study
FDA	Food and Drug Administration
IRB	Institutional Review Board
OCT	Ocular Coherence Tomography
RBZ	Ranibizumab
READ-3	Ranibizumab for Edema of the mAcula in Diabetes - Protocol 3
SD-OCT	Spectral domain ocular coherence tomography
TD-OCT	Time-domain ocular coherence tomography
VEGF	Vascular Endothelial Growth Factor

Abstract

Purpose

To determine whether clinically meaningful changes in best-corrected visual acuity (BCVA) can precede or coincide with changes in central retinal thickness (CRT) in diabetic macular edema (DME) under a treat-and-extend regimen, even after complete resolution of macular edema.

Design

Post-hoc analysis of the READ-3 clinical trial.

Participants

21 eyes from 21 READ-3 participants who achieved CRT <250 µm (no OCT-detectable edema) at 6 months.

Methods

Patients received 5 monthly ranibizumab injections (loading phase), then were monitored monthly through 24 months with as-needed retreatment if OCT showed recurrent edema (treat-and-extend phase). We defined a significant BCVA change as ≥4 ETDRS letters and a significant CRT change as ≥30 µm on OCT, and we analyzed the temporal “B-C lag” between functional (BCVA) and anatomical (CRT) changes.

Main Outcome Measures

Timing and sequence of BCVA vs. CRT changes per patient, and injection-free interval durations.

Results

Mean age was 65.6 ± 10.7 years. By month 6 (post-loading), all 21 eyes had resolved edema (CRT <250 µm). In this initial treatment phase, 9 eyes (42.9%) showed BCVA improvement (≥4 letters) concurrently with CRT reduction (≥30 µm); 8 eyes (38.1%) showed BCVA improvement one month after CRT improvement; and 4 eyes (19.0%) exhibited a longer BCVA lag of 2–5 months. During the 6–24 month treat-and-extend phase, BCVA and CRT changes coincided in

5 eyes (23.8%). In another 5 eyes (23.8%), a BCVA decline preceded any CRT increase by a median of 3 months (range 1–12), serving as an early warning of relapse. Four eyes (19.0%) showed CRT thickening prior to BCVA loss. The remaining 7 eyes (33.3%) had no observed recurrent edema or vision loss during follow-up, owing to proactive retreatment before changes manifested.

Conclusions

In this post-hoc analysis, BCVA fluctuations often mirror CRT changes and, in some cases, **preceded** structural relapse. These findings suggest BCVA monitoring could serve as an independent indicator of DME activity, potentially enabling earlier intervention in a treat-and-extend paradigm even after the macula is initially dried. A home BCVA monitoring strategy, if validated, might reduce reliance on OCT for routine surveillance and improve patient outcomes where access to OCT is limited.

Introduction

Diabetic macular edema (DME) is a leading cause of preventable vision loss among working-age individuals with diabetic retinopathy (DR)[1]. The advent of intravitreal anti-VEGF therapy has revolutionized DME management, yielding significant visual gains in clinical trials. Historically, regulatory approval and trial endpoints have centered on functional improvements – specifically BCVA gains[2,3]. However, in routine practice ophthalmologists often rely on optical coherence tomography (OCT) findings, such as changes in central retinal thickness (CRT) or central subfield thickness (CST), to guide re-treatment. This shift toward anatomical endpoints reflects the assumption that retinal thickening correlates with, and even precedes, vision loss[4].

In reality, the structure-function relationship in DME is complex and variable. Not all patients experience parallel improvements in BCVA and CRT. Real-world data suggest that fewer than 25% of eyes achieve both a dry macula and BCVA 20/40 after nine anti-VEGF injections[5]. Such misalignment means some patients have persistent vision impairment despite resolved edema, while others maintain good vision despite residual edema. If physicians treat based solely on OCT abnormalities, patients might receive injections even when functional vision is stable. This discordance can lead to overly aggressive treatment schedules and increases the burden of frequent clinic visits and injections on patients and healthcare systems. Conversely, monitoring primarily by OCT may delay detection of functional decline in cases where BCVA worsens before obvious OCT changes. In such scenarios, insisting on costly, monthly OCT monitoring for every patient may become impractical.

There is thus a pressing need for practical, cost-effective remote monitoring solutions that can detect disease activity as a timely and patient-centric alternative without over-reliance on clinic-based OCT. We hypothesize that clinically meaningful changes in BCVA (≥4 ETDRS

letters) might serve as an early indicator of DME activity, occurring concurrently with or even ahead of CRT changes, including in eyes that have been successfully treated to resolution of edema. To explore this hypothesis, we performed a post-hoc analysis of the READ-3 trial[6] – a prospective, multicenter DME study with high-frequency OCT and BCVA follow-up. We focused on the subset of patients who achieved complete macular edema resolution after initial therapy. By analyzing the lag between functional and anatomical changes during a treat-and-extend protocol, we aimed to determine whether BCVA alone could reliably signal disease progression. We also considered the implications for a home-based BCVA monitoring system that could complement or substitute for OCT in routine DME management.

Methods

Study Design and Population

This is a post-hoc analysis of READ-3 (Ranibizumab for Edema of the mAcula in Diabetes, Protocol 3), a 24-month randomized clinical trial conducted at 13 U.S. sites. The trial enrolled adults with DME meeting typical inclusion criteria, including baseline CST ≥250 µm on time-domain OCT and BCVA 20/40 to 20/320 (ETDRS letters). Key exclusion criteria were recent macular laser or intraocular steroid, or anti-VEGF treatment within 2–3 months. Each patient contributed one study eye; if both were eligible, the eye with greater CST was selected. All participants provided informed consent, and the study adhered to the Declaration of Helsinki and was registered on clinicaltrials.gov (NCT01077401)[7].

Treatment Protocol

Enrolled eyes were randomized 1:1 to monthly intravitreal ranibizumab 0.5 mg or 2.0 mg for 5 consecutive months (baseline through Month 5). Month 6 was the primary endpoint of the trial. After Month 6, treat-and-extend management was implemented: patients were evaluated monthly and received additional ranibizumab injections only if OCT showed recurrent macular edema (central subfield thickness ≥250 µm on time-domain OCT, or any macular fluid detected on time-domain or spectral-domain OCT). If no edema was present, the injection could be deferred, and the patient examined again the following month. (Note: This regimen is effectively a pro re nata (PRN, as-needed) approach with monthly monitoring; for simplicity we refer to it as “treat-and-extend,” although no fixed extension interval was predetermined beyond monthly evaluations.) All study visits included BCVA measurement (ETDRS protocol[8] by certified examiners), OCT imaging, and ophthalmic examinations.

Outcome Measures

For the present analysis, we identified 21 eyes (of 155 eyes in READ-3) that achieved complete resolution of edema by the Month 6 visit, defined as CRT <250 µm with no intraretinal or subretinal fluid visible on OCT. These 21 eyes (one per patient) formed our study cohort for evaluating BCVA-CRT dynamics after successful initial treatment. We tracked two main outcomes: (1) Lag between functional and anatomical changes – specifically, whether BCVA changes occurred before, at the same time, or after corresponding CRT changes; and (2) Injection-free interval – the duration each eye remained free of re-injection after Month 6, which reflects how long edema stayed in remission. For completeness, we also recorded any BCVA or CRT changes during the initial monthly treatment phase (Months 0–5) to compare the synchronization of improvements during intensive therapy.

Definitions

A clinically significant BCVA change was defined as a gain or loss of ≥4 letters from the previous visit (approximately equivalent to ≥0.08 logMAR change), based on test-retest variability of ETDRS charts and prior definitions of meaningful change. A significant CRT change was defined as an increase or decrease of >30 µm on OCT, consistent with thresholds used in DME studies for meaningful edema fluctuation. A BCVA–CRT lag was said to occur if a significant change in BCVA was not observed in the *same* visit as a significant change in CRT for that eye. In other words, if one parameter changed at visit n and the other changed at a later visit $n+x$ (or had changed earlier at $n–x$), we considered a lag of x months to be present. By this definition, BCVA-leading cases are those where BCVA change came first, CRT-leading cases where CRT changed first, and concurrent cases where both changed in the same month (lag = 0). Eyes that never met the criteria for recurrent change (no significant BCVA or CRT worsening during follow-up) were tracked as well.

Data Analysis

We used descriptive statistics to summarize patient baseline characteristics and the distribution of lag categories. For each eye, we noted the timing (month) of any significant BCVA drop (≥4-letter loss) and any significant CRT increase (≥30 µm rise) during the treat-and-extend phase. We then categorized each eye according to the sequence of events (BCVA first, simultaneous, CRT first, or no event). A Kaplan–Meier survival analysis for time to edema recurrence(or time to first re-injection) was considered to illustrate the range of injection-free intervals, although given the small sample it was used descriptively rather than for inferential statistics. All analyses were performed using Stata 15.1 (StataCorp, College Station, TX).

.

Results

Patient Characteristics

The 21 patients had a mean age of 65.6 ± 10.7 years; 57% were female (12/21). All had type 1 or type 2 diabetes with DME and had received 5 monthly ranibizumab injections as per protocol. At baseline, the mean CRT was elevated (mean ~450 µm) and mean BCVA was moderately impaired (approximately 60 ETDRS letters, ~20/63 Snellen) *(exact baseline values to be tabulated in Table 2)*. By Month 6, after the loading phase, mean CRT improved substantially (to ~240 µm) and mean BCVA improved by ~8 letters (final BCVA ~68 letters, ~20/50) *(values to be verified from source data)*. All 21 eyes had CRT <250 µm at Month 6, confirming complete edema resolution in this subgroup.

Initial Treatment Phase (Months 0–6)

During the monthly injection phase, functional improvement often lagged anatomical improvement. Among these 21 eyes, 9 (42.9%) demonstrated simultaneous CRT reduction (≥30 µm decrease) and BCVA gain (≥4 letters) at the same visit. In 8 eyes (38.1%), BCVA improvement occurred one month after the OCT-confirmed reduction in CRT. An additional 4 eyes (19.0%) showed a longer delay, with BCVA gains appearing only 2–5 months after the initial CRT improvement (median lag of 4 months). These findings indicate that even under continuous monthly therapy, some patients' visual acuity did not rebound immediately despite rapid resolution of edema. A small number of eyes (approximately 2 in this cohort) had only minimal BCVA improvement by the end of loading despite anatomical success *(e.g., due to chronic photoreceptor damage)* – in those cases BCVA never reached the ≥4-letter gain threshold, an observation requiring author verification. Nonetheless, no cases showed BCVA improving significantly before CRT in the initial phase; functional gains were either concurrent with or after structural drying of the macula.

Treat-and-Extend Phase (Months 6–24)

In the injection-extension phase, patients were monitored for the recurrence of DME. The median follow-up in this phase was 18 months (range 6–18, up to study end at 24 months). Thirteen of the 21 eyes (61.9%) experienced at least one episode of recurrent edema meeting re-treatment criteria during this period. **Figure 1** illustrates the timing of BCVA and CRT changes for each patient, and **Figure 2** summarizes the distribution of patients by the lag category:

As shown in **Figure 1**, 5 eyes (23.8%) had BCVA decline preceding CRT increase (BCVA-leading cases). In these eyes, BCVA dropped by ≥4 letters a median of 3 months *earlier* than any detectable CRT rise (range of lead time: 1 to 12 months). For example, one patient noted a mild vision drop approximately one year before OCT finally confirmed edema recurrence. In 5 eyes (23.8%), BCVA and CRT worsened simultaneously, with both criteria met at the same visit. In 4 eyes (19.0%), CRT worsening was observed before any BCVA loss (CRT-leading cases). On average, these CRT-first cases had only a short lag (approximately 1–2 months) before vision began to decline, though one eye maintained stable BCVA for a few months despite increasing CST. The remaining 7 eyes (33.3%) had no significant recurrence of edema or vision loss during the study; notably, all 7 had continued to receive periodic injections at extended intervals (e.g., every 8–12 weeks) as a prophylactic measure, which likely helped maintain a dry macula and stable vision. In those cases, we did not observe a lag because neither parameter crossed the pre-specified threshold (these eyes can be considered “censored” in time-to-event analyses).

The injection-free intervals (time from month 6 to first re-treatment) varied widely across patients, reflecting the heterogeneity of disease activity. Among eyes that recurred, the first re-

injection was given as early as 1-month post-primary endpoint in some cases, whereas other eyes required no retreatment for a year or more. For instance, one eye remained injection-free for 18 months before any worsening occurred, whereas another needed retreatment at month 7. A Kaplan–Meier analysis (not shown) demonstrates this spread: by 6 months into extension, approximately 40% of eyes had required an injection; by 12 months, ~60% had; and roughly one-third of eyes never needed retreatment through 18–24 months. The median injection-free survival was approximately 10–12 months *(this median is an estimate; exact value to be confirmed by analysis)*. Importantly, in those BCVA-leading eyes, the BCVA drop often prompted closer observation but not an immediate injection (since OCT was still dry); consequently, their injection was administered only when OCT finally revealed edema, which was a median of 3 months later. This suggests a window of opportunity where an earlier intervention *could* have been considered if the BCVA drop were taken as a harbinger of relapse.

Discussion

Our post-hoc analysis of the READ-3 trial under a treat-and-extend paradigm provides intriguing evidence that BCVA monitoring can serve as an early and independent indicator of disease activity in DME. In a cohort of patients who had initially achieved a dry macula, we observed that BCVA changes often paralleled or even anticipated structural changes during follow-up. Notably, approximately 24% (5/21) showed functional deterioration (vision loss) *preceding* any OCT-detectable fluid recurrence, in some cases by several months. This finding raises the possibility that, for select patients, declining BCVA alone could signal impending edema relapse well before OCT confirms it. To our knowledge, this is one of the first analyses to explicitly demonstrate such a lag in DME after initial successful therapy. It challenges the common assumption[9] that “anatomical changes precede functional declines” in all cases of DME and highlights a subset where the opposite is true.

At the same time, our results reinforce that BCVA and OCT outcomes do not always move in lockstep. In the initial treatment phase, some patients achieved substantial CRT reduction yet experienced delayed or minimal vision improvement – echoing real-world observations that anatomy and function can diverge. Similarly, during extension, we saw examples of eyes maintaining good vision for a while despite OCT recurrence (CRT-first cases), as well as eyes with vision loss out of proportion to OCT findings. These scenarios underscore the multifactorial nature of DME: factors like photoreceptor damage, macular ischemia, or duration of edema can affect BCVA recovery independently of central thickness[3,10]. Such discordances are not unique to DME; studies in retinal vein occlusion and uveitic macular edema have reported that OCT changes and BCVA gains can diverge, especially in the short term[11–14]. Our data in DME align with those reports, emphasizing the need for clinicians to monitor both aspects. In practice, improvement in CRT without commensurate BCVA gain should prompt a search for

other limiting factors (e.g., retinal atrophy or diabetic cataract), while BCVA decline without OCT changes should raise suspicion for early relapse or alternative pathology (e.g., subtle vitreo-macular interface changes or capillary non-perfusion).

Crucially, because BCVA is the gold standard for visual function, these findings support a greater role for BCVA-driven monitoring in DME management. If a patient (or a home monitoring system) detects an early BCVA drop, even a small but significant one, clinicians could intervene sooner – potentially preventing more serious edema build-up or irreversible neuroretinal damage. In our series, earlier intervention at the point of BCVA decline (rather than waiting for OCT confirmation) might have reduced the duration of edema in those BCVA-leading eyes, possibly preserving a few letters of acuity that were lost. This concept dovetails with the DRCR Retina Network's Protocol V findings[15], where observation (no immediate treatment) in center-involved DME with good vision was found to be safe in the short term. That study suggested some eyes can tolerate edema without vision loss, but it also underscored the importance of close follow-up: patients were monitored regularly and treated if BCVA worsened. Our results extend this idea that monitoring BCVA closely is not only an option when initial vision is good, but also a potentially sensitive way to catch recurrences in a treat-and-extend scenario.

From a health systems perspective, home-based BCVA monitoring could be a game-changer, especially as we move toward longer-lasting DME treatments. Currently, while home OCT devices are being developed (e.g., home OCT for age-related macular degeneration), these are costly and require advanced technology and infrastructure. By contrast, BCVA testing needs only a reliable method to display optotypes at the correct size and distance. If an FDA-approved home vision test could replicate standardized 4-meter ETDRS acuity (perhaps via a smartphone app or a simple device) and securely transmit data to clinicians, it would dramatically reduce the need for patients to come in solely for monitoring. This is particularly pertinent for DME patients, who often are elderly and may have mobility or transportation challenges. It is also vital for

patients in low- and middle-income regions, where the burden of diabetes is high and access to OCT may be very limited. A low-cost, widely accessible vision-based monitoring strategy could enable more frequent assessments without overwhelming clinic capacity.

There are already proof-of-concept studies[16,17] suggesting feasibility: small trials have shown that smartphone-based vision check apps (using device cameras, virtual reality headsets, or motion sensors) can achieve near-clinic accuracy in measuring visual acuity under controlled conditions. However, none of these tools have yet been validated on a large scale in diabetics at risk for macular edema recurrence. Importantly, no existing app fully adheres to the ETDRS protocol (with standardized lighting, distance, crowding, etc.) or has regulatory approval. Our findings provide a strong rationale to prioritize developing such technology. If BCVA can indeed detect meaningful changes earlier in some patients, a reliable home test could prompt timely clinic visits or even telemedicine consultations for OCT and treatment. In effect, BCVA-based home monitoring, augmented by telemedicine, could shift care toward a more proactive and patient-centered model.

The timing of monitoring is another consideration. Our data reinforce that monthly assessments are valuable – all our lag calculations were based on monthly intervals, and it was within monthly visits that these changes were captured. This aligns with the standard loading phase frequency and early extension phase in DME treatment, where monthly check-ins are common until stability is achieved. The DRCR Network has shown that after initial stabilization, follow-up intervals can be personalized (lengthened or shortened) based on disease activity[3]. Our results add that while some patients may not need monthly OCT once stable, monthly BCVA self-checks could still be prudent to detect any functional slippage between infrequent office visits. In high-resource settings, such data could refine treat-and-extend injection intervals (e.g., calling patients back sooner if home acuity drops). In lower-resource settings, monthly

home BCVA monitoring could be a stopgap for those who cannot afford frequent clinic OCT – a significant public health advantage given the global diabetes epidemic.

In conclusion, while both BCVA and OCT remain invaluable for managing DME, our analysis suggests that BCVA can function as an early warning signal of disease reactivation in a significant subset of patients. Developing an accurate home-based BCVA monitoring system could be a transformative step toward more accessible and proactive DME care. Our data support the notion that a four-week (monthly) monitoring interval is clinically meaningful for capturing the interplay between vision and retinal structure. Bridging the gap between clinic and home, BCVA-guided monitoring (supplemented by OCT as needed and expert oversight) may ultimately improve outcomes and reduce treatment burden in DME. As we move toward longer-lasting treatments and seek to globalize care, leveraging the simplicity and scalability of visual acuity measurement offers a promising avenue to ensure that no decline in vision goes unnoticed.

Study Limitations

We acknowledge several limitations to this analysis. First, the study is a retrospective post-hoc analysis of a relatively small subgroup (n=21) from a single clinical trial. The findings, while hypothesis-generating, may not generalize to all DME patients. READ-3 had rigorous monthly follow-up and ETDRS vision testing[7]; real-world settings with less frequent visits or non-ETDRS acuity measurements might yield different results. Second, our definition of “significant” change (4 letters, 30 µm) was chosen based on practical thresholds, but smaller changes could be meaningful over longer periods. It’s possible that micro-fluctuations in BCVA or CRT not meeting our criteria could precede larger changes. Third, confounding factors could influence BCVA independent of macular edema – for example, cataract progression could cause a slow BCVA decline unrelated to retinal thickening. We attempted to attribute BCVA changes to DME by requiring concurrent or subsequent edema to label an event, but we cannot fully exclude

other causes of vision change. Eyes with diabetic cataract or other comorbidities might muddy the relationship between BCVA and CRT. Fourth, our treat-and-extend regimen was effectively monthly PRN monitoring; thus, some eyes received injections before relapse (preventing observation of a natural lag in those cases). While this reflects real clinical practice – since physicians often treat preemptively – it means we had to classify 7 eyes as “no observable change” when in fact they might have relapsed if we had waited longer. This could bias the proportions of lag categories. A prospective study that withholds treatment until certain criteria are met might better quantify true lag frequencies but would raise ethical questions. Finally, our analysis of correlation and visual outcomes was limited by sample size, precluding definitive conclusions about long-term vision impact. The observation that vision was generally recoverable after retreatment should be interpreted cautiously; a larger dataset is needed to confirm that no harm comes from waiting for OCT changes if BCVA has already dropped.

Implications and Future Directions

Despite these limitations, our findings support a paradigm shift wherein BCVA is not merely an outcome measure but a practical monitoring tool in DME. We envision a future DME management algorithm where patients use a certified home vision test weekly or monthly, and any confirmed ≥5-letter decline triggers a prompt clinic evaluation (or perhaps even direct scheduling of an injection, if corroborated by other data). This could reduce unnecessary visits (for those doing well) and also catch relapses sooner, optimizing treatment timing. Importantly, this approach aligns with the fact that regulatory approvals for DME therapies hinge on BCVA improvement; it makes sense to also use BCVA to guide day-to-day management, keeping the focus on what ultimately matters: the patient’s vision. With longer-acting drugs reducing visit frequency, such a scheme becomes even more attractive – fewer clinic visits overall, and those that do occur are prompted by a real indication of change. To realize this vision, further research is needed. A prospective trial could test a BCVA-monitored strategy against an OCT-

monitored strategy, measuring outcomes like number of clinic visits, injections given, vision loss prevented, and patient quality-of-life. Additionally, developing robust, user-friendly home BCVA testing technology is paramount. Such tools must replicate standardized conditions and minimize variability, perhaps by calibrating device screen size, viewing distance, and ambient illumination. Integrating these tools with telemedicine platforms and electronic health records would allow seamless alerts to providers when a patient's acuity crosses a threshold. Artificial intelligence could further assist by analyzing trends and false positives/negatives in patient-reported data.

Conclusion

In summary, this post-hoc analysis of READ-3 highlights that clinically meaningful BCVA changes can coincide with or precede OCT changes in the management of DME. A subset of patients showed vision loss as the first sign of relapse, underscoring that BCVA is not merely a passive outcome but can be an active monitoring tool. Given practical considerations of cost, access, and patient burden, an accurate home BCVA assessment strategy could substantially enhance DME monitoring. Such an approach would realign daily practice with the functional outcomes that define success in clinical trials. Our findings provide a proof of concept that monthly observation of BCVA (even without OCT) can yield actionable information – potentially enabling timely retreatment and preventing avoidable vision loss. BCVA-guided decision-making, combined with clinical judgment and periodic OCT as needed, may thus represent a reliable and efficient strategy for long-term DME care. Further prospective studies are warranted to validate these findings, compare functional vs. anatomical monitoring protocols, and explore additional functional markers. By advancing home vision-monitoring tools and incorporating them into treat-and-extend regimens, we can move toward a more patient-centric, scalable model of DME management that maintains vision and quality of life for millions at risk.

References

1. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. *Diabetes.* 1995;44(8):968-983.
2. Intravitreal Aflibercept for Diabetic Macular Edema - Ophthalmology. Accessed July 13, 2025. https://www.aaojournal.org/article/S0161-6420(14)00426-6/fulltext
3. Tang T, Tran D, Han D, Zeger SL, Crews DC, Cai CX. Place, Race, and Lapses in Diabetic Retinopathy Care. *JAMA Ophthalmol*. 2024;142(6):581-583. doi:10.1001/jamaophthalmol.2024.0974
4. The Relationship between OCT-measured Central Retinal Thickness and Visual Acuity in Diabetic Macular Edema. *Ophthalmology*. 2007;114(3):525-536. doi:10.1016/j.ophtha.2006.06.052
5. Blinder KJ, Dugel PU, Chen S, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). *Clin Ophthalmol Auckl NZ*. 2017;11:393-401. doi:10.2147/OPTH.S128509
6. Do DV, Sepah YJ, Boyer D, et al. Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). *Eye Lond Engl*. 2015;29(12):1538-1544. doi:10.1038/eye.2015.142
7. Johns Hopkins University. *Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study*. clinicaltrials.gov; 2017. Accessed July 13, 2025. https://clinicaltrials.gov/study/NCT01077401
8. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. *Ophthalmology*. 1991;98(5 Suppl):741-756. doi:10.1016/s0161-6420(13)38009-9

9. Zhang CH, Gong B, Huang C, et al. Morphological and functional changes in the macular area in diabetic macular edema after a single intravitreal injection of aflibercept. *Int J Ophthalmol*. 2023;16(1):88-94. doi:10.18240/ijo.2023.01.13
10. Moon BG, Um T, Lee J, Yoon YH. Correlation between Deep Capillary Plexus Perfusion and Long-Term Photoreceptor Recovery after Diabetic Macular Edema Treatment. *Ophthalmol Retina*. 2018;2(3):235-243. doi:10.1016/j.oret.2017.07.003
11. Yiu G, Welch RJ, Wang Y, Wang Z, Wang PW, Haskova Z. SD-OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema due to Retinal Vein Occlusion. *Ophthalmol Retina*. 2020;4(1):67-76. doi:10.1016/j.oret.2019.08.009
12. Sen P, Gurudas S, Ramu J, et al. Predictors of Visual Acuity Outcomes after Anti–Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion. *Ophthalmol Retina*. 2021;5(11):1115-1124. doi:10.1016/j.oret.2021.02.008
13. Iannetti L, Scarinci F, Alisi L, et al. Correlation between Morphological Characteristics of Macular Edema and Visual Acuity in Young Patients with Idiopathic Intermediate Uveitis. *Medicina (Mex)*. 2023;59(3):529. doi:10.3390/medicina59030529
14. Matas J, Llorenç V, Fonollosa A, et al. Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis. *PLoS ONE*. 2019;14(1):e0210799. doi:10.1371/journal.pone.0210799
15. Baker CW, Glassman AR, Beaulieu WT, et al. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. *JAMA*. 2019;321(19):1880-1894. doi:10.1001/jama.2019.5790
16. Karampatakis V, Almaliotis D, Talimtzi P, Almpanidou S. Design and Validation of a Novel Smartphone-Based Visual Acuity Test: The K-VA Test. *Ophthalmol Ther*. 2023;12(3):1657-1670. doi:10.1007/s40123-023-00697-x

17. Bastawrous A, Rono HK, Livingstone IAT, et al. Development and Validation of a Smartphone-Based Visual Acuity Test (Peek Acuity) for Clinical Practice and Community-Based Fieldwork. *JAMA Ophthalmol*. 2015;133(8):930-937. doi:10.1001/jamaophthalmol.2015.1468



Appendix

Figure 1. Patient-level timelines of significant BCVA and CRT changes during the treat-and-extend phase. Each row represents one eye. Blue circles denote a ≥4-letter BCVA decline (functional worsening) and red squares denote a ≥30 µm CRT increase (anatomical worsening). Arrows indicate the sequence from the first change to the second change when they did not coincide. Green stars at 24 months mark eyes with no recurrence observed (no significant changes, as they remained dry under continuous extend therapy). In the example above, Patient 1 (row 1) experienced a BCVA drop at month 7 followed by a CRT increase at month 8 (BCVA-leading by 1 month), whereas Patient 6 had a CRT rise at month 7 and subsequent BCVA loss at month 8 (CRT-leading by 1 month). Several patients (e.g., #10, #11) showed concurrent changes (blue and red symbols overlapping in time). Seven patients (rows 15–21) exhibited no significant CRT or BCVA worsening through the end of follow-up, likely due to preemptive injections keeping them dry. This heatmap-like visualization highlights substantial inter-patient variability in the lag between functional and anatomical indicators of relapse.



Figure 2. Distribution of patients by BCVA-CRT lag category during the extension phase. Among 21 eyes with resolved edema at month 6, 5 (24%) experienced BCVA decline before any CRT increase, 5 (24%) had simultaneous BCVA and CRT changes at recurrence, 4 (19%) had CRT worsen before BCVA, and 7 (33%) had no OCT/BCVA changes due to ongoing treatment preventing relapse. This bar chart underscores that in a substantial subset of eyes (yellow + blue segments totaling ~48%), functional deterioration was not preceded by an OCT-detectable thickness increase – BCVA either gave an earlier signal or was the sole indicator of relapse. Meanwhile, ~19% had purely OCT-led detection, and one-third remained quiescent under extended therapy.